Incidence and prevalence of NMOSD in Australia and New Zealand

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 88, Issue 8, 2017, Pages 632-638

  Bukhari, Wajih ^a   Prain, Kerri M ^b   Waters, Patrick ^c   Woodhall, Mark ^c   O'Gorman, Cullen M ^a   Clarke, Laura ^a   Silvestrini, Roger A ^d   Bundell, Christine S ^e   Abernethy, David ^f   Bhuta, Sandeep ^a   Blum, Stefan ^g   Boggild, Mike ^h   Boundy, Karyn ⁱ   Brew, Bruce J ^j   Brown, Matthew ^k   Brownlee, Wallace J ^l   Butzkueven, Helmut ^m   Carroll, William M ^e   Chen, Celia ⁿ   Coulthard, Alan ^o,p   Dale, Russell C ^q   Das, Chandi ^r   Dear, Keith ^s   Fabis Pedrini, Marzena J ^t   Fulcher, David ^u   Gillis, David ^o   Hawke, Simon ^u   Heard, Robert ^q   Henderson, Andrew P D ^d   Heshmat, Saman ^a   Hodgkinson, Suzanne ^v   Jimenez Sanchez, Sofia ^a   Killpatrick, Trevor ^m   King, John ^m   Kneebone, Christopher ⁱ   Kornberg, Andrew J ^m   Lechner Scott, Jeannette ^x   Lin, Ming Wei ^u   Lynch, Christpher ^y   Macdonell, Richard ^z   Mason, Deborah F ^aa   McCombe, Pamela A ^o   Pender, Michael P ^o   Pereira, Jennifer A ^y   Pollard, John D ^ab   Reddel, Stephen W ^ab   Shaw, Cameron ^ac   Spies, Judith ^u   Stankovich, James ^ad   Sutton, Ian ^j   Vucic, Steve ^d   Walsh, Michael ^o   Wong, Richard C ^o   Yiu, Eppie M ^ae   Barnett, Michael H ^ab   Kermode, Allan G ^t   Marriott, Mark P ^m   Parratt, John D E ^af   Slee, Mark ^ag   Taylor, Bruce V ^ad   Willoughby, Ernest ^ah   Wilson, Robert J ^b   Vincent, Angela ^c   Broadley, Simon A ^a,w   more..

^a GRIFFITH UNIVERSITY   (Australia)

^b Pathology Queensland ^*  (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f WELLINGTON HOSPITAL   (New Zealand)

^g PRINCESS ALEXANDRA HOSPITAL   (Australia)

^h TOWNSVILLE HOSPITAL   (Australia)

ⁱ ROYAL ADELAIDE HOSPITAL   (Australia)

^j ST VINCENT S HOSPITAL   (Australia)

^k QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^l University College London   (United Kingdom)

^m UNIVERSITY OF MELBOURNE   (Australia)

ⁿ FLINDERS UNIVERSITY   (Australia)

^o UNIVERSITY OF QUEENSLAND   (Australia)

^p ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^q University of Sydney   (Australia)

^r CANBERRA HOSPITAL   (Australia)

^s DUKE KUNSHAN UNIVERSITY   (China)

^t Western Australian Biomedical Research Institute   (Australia)

^u UNIVERSITY OF SYDNEY   (Australia)

^v UNIVERSITY OF NEW SOUTH WALES   (Australia)

^w GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^x HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^y UNIVERSITY OF AUCKLAND   (New Zealand)

^z AUSTIN HEALTH   (Australia)

^aa CHRISTCHURCH HOSPITAL   (New Zealand)

^ab UNIVERSITY OF SYDNEY   (Australia)

^ac GEELONG HOSPITAL   (Australia)

^ad UNIVERSITY OF TASMANIA   (Australia)

^ae ROYAL CHILDREN'S HOSPITAL   (Australia)

^af ROYAL NORTH SHORE HOSPITAL   (Australia)

^ag FLINDERS MEDICAL CENTRE   (Australia)

^ah AUCKLAND CITY HOSPITAL   (New Zealand)

more..

Author keywords

Ancestry; Epidemiology; Incidence; Neuroimmunology; Prevalence

Indexed keywords

AQUAPORIN 4 ANTIBODY; AQUAPORIN 4;

ADOLESCENT; ADULT; AGED; ANCESTRY GROUP; ANTIBODY DETECTION; ARTICLE; ASIAN; AUSTRALIA; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST; EUROPEAN; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEW ZEALAND; PATIENT CARE; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; VERY ELDERLY; YOUNG ADULT; IMMUNOLOGY;

AQUAPORIN 4; AUSTRALIA; HUMANS; INCIDENCE; NEUROMYELITIS OPTICA; NEW ZEALAND; PREVALENCE;

EID: 85024392871     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2016-314839     Document Type: Article

References (42)

1. Bukhari W, Barnett MH, Prain K, et al. Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci 2012;13:12970-93.
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.
3. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010;6:383-92.
4. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15.
5. Ochi H, Fujihara K. Demyelinating diseases in Asia. Curr Opin Neurol 2016;29:222-8.
6. Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008;118:209-17.
7. Etemadifar M, Nasr Z, Khalili B, et al. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Mult Scler Int 2015;2015:1-8.
8. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.
9. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180-5.
10. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78:665-71. discussion 69.
11. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.
12. Ahmad OB, Boschi-Pinto C, Lopez AD, et al. Age standardization of rates: a new WHO standard. GPE Discussion Paper Series: WHO 2001.
13. Lincoln FC. Calculating waterfowl abundance on the basis of banding returns. Washington, DC: U.S. G.P.O, 1930.
14. Southwood TRE, Henderson PA. Ecological methods. 3rd ed. Oxford, UK: Blackwell Science Ltd, 2000.
15. National population estimates (Web page). Statistic New Zealand. 2016 http://www.stats.govt.nz/browse-for-stats/population.aspx (accessed 23 Apr 2016).
16. Population: Australian Bureau of Statistics. 2016 http://www.abs.gov.au/Population (accessed 23 Apr 2016).
17. Google Maps: Google. 2016 https://www.google.com.au (accessed 23 Apr 2016).
18. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016:775-83.
19. Asgari N, Lillevang ST, Skejoe HP, et al. A population-based study of neuromyelitis optica in Caucasians. Neurology 2011;76:1589-95.
20. Profiles of disability, Australia: Australian Bureau of Statistics; 2009. 2016 http://www.abs.gov.au/ausstats/abs@nsf/Lookup/4429.0Main+Features100182009 (accessed 3 May 2016).
21. Taylor BV, Pearson JF, Clarke G, et al. MS prevalence in New Zealand, an ethnically and latitudinally diverse country. Mult Scler 2010;16:1422-31.
22. Alla S, Pearson JF, Taylor BV, et al. An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand. Mult Scler 2016;22:705-7.
23. McLeod JG, Hammond SR, Hallpike JF. Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust 1994;160:117-22.
24. Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, et al. An epidemiological study of neuromyelitis optica in Cuba. J Neurol 2009;256:35-44.
25. Cossburn M, Tackley G, Baker K, et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 2012;19:655-9.
26. Jacob A, Panicker J, Lythgoe D, et al. The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 2013;260:2134-7.
27. Etemadifar M, Dashti M, Vosoughi R, et al. An epidemiological study of neuromyelitis optica in Isfahan. Mult Scler 2014;20:1920-2.
28. Kashipazha D, Mohammadianinejad SE, Majdinasab N, et al. A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran. Iran J Neurol 2015;14:204-10.
29. Nagaishi A, Takagi M, Umemura A, et al. Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry 2011;82:1360-4.
30. Barhate KS, Ganeshan M, Singhal BS. A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Ann Indian Acad Neurol 2014;17:77-81.
31. Pandit L, Kundapur R. Prevalence and patterns of demyelinating central nervous system disorders in urban Mangalore, South India. Mult Scler 2014;20:1651-3.
32. Yin J, Long Y, Shan F, et al. Clinical manifestations of neuromyelitis optica in male and female patients. Neurol Res 2015;37:967-73.
33. Daoudi S, Bouzar M. Neuromyelitis optica spectrum disorders in Algeria: a preliminary study in the region of Tizi Ouzou. Mult Scler Relat Disord 2016;6:37-40.
34. Rivera JF, Kurtzke JF, Booth VJ, et al. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol 2008;255:710-5.
35. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-17.
36. Collongues N, Marignier R, Zéphir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010;74:736-42.
37. Aboul-Enein F, Seifert-Held T, Mader S, et al. Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS One 2013;8:e79649.
38. Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 2016;86:245-52.
39. Sepúlveda M, Armangué T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 2016;3:e225.
40. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016;79:206-16.
41. Lana-Peixoto MA, Callegaro D. The expanded spectrum of neuromyelitis optica: evidences for a new definition. Arq Neuropsiquiatr 2012;70:807-13.
42. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-14.